跳至主要内容
临床试验/NCT07409480
NCT07409480尚未招募不适用

Design and Development of a Functional Plant-based Beverage to Improve Nutritional Status and Immunity for the Early Elderly People to Get Well-healthy Ageing

University Rovira i Virgili1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2026年2月9日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
70
试验地点
1
主要终点
Change in serum hsCRP

研究概览

简要总结

In 2018, for the first time, the number of people aged 65 and over exceeded the number of children under the age of 5. A rise in ageing societies is coming, and new efforts are needed to ensure that this increase in life expectancy is accompanied by years of health and a good quality of life. The new focus for our ageing society will be an extended healthspan, the period of life spent in good health. This is an important shift, as population ageing is a defining global trend of our time. By 2030, 1 in 6 people in the world will be 60 years and older, according to the World Health Organization. In this sense, the imperative to maintain the health and activity levels of the senior demographic has never been more critical. Advances in healthcare, science, and technology have contributed to increased longevity, yet this does not always equate to improved health.

The prevalence of malnutrition or the risk thereof among the elderly living independently in Europe ranges from 13.5% to 29.7%, highlighting a pressing need for nutritional intervention. Addressing this, the pursuit of innovative nutritional sources and the creation of new food products enriched with these sources are essential to bridging the nutritional gap, ensuring healthier aging prospects for this population. The formulation of food products tailored to the elderly must consider their unique nutritional requirements, particularly concerning protein and micronutrient intake. Recent advances in food technology facilitate the development of plant-based beverages that are palatable, nutritionally adequate, and accessible. Moreover, the growing market share of plant-based non-dairy beverages provides a promising alternative, offering opportunities to deliver bioactive compounds with health-promoting properties, appealing to health-conscious and lactose-intolerant consumers.

Given the nutritional challenges and health risks faced by the aging population, particularly in relation to protein intake and malnutrition, another critical aspect that warrants attention is the immune system's health through diet. The immune system, which naturally weakens with age, plays a crucial role in the elderly's ability to resist infections and recover from illnesses. Research highlights the impact of not only macronutrients but micronutrients such as vitamins D, C, E, and zinc on enhancing immune responses, suggesting that diets rich in these nutrients can significantly benefit immune health in older adults. Strengthening the immune system through diet becomes even more pertinent considering the increased vulnerability of the elderly to infectious diseases, including respiratory infections like influenza and pneumonia, which are leading causes of morbidity and mortality in this population. Developing food products that are not only nutritionally adequate but also tailored to support immune function could provide a dual benefit: improving general health and enhancing the body's defence mechanisms.

The present research project is structured into three coordinated phases and is enabled by the multidisciplinary nature of the IMMUGOLD consortium. In the first phase, AZTI conducted an extensive literature and technical review to identify functional ingredients capable of supporting immune function while remaining compatible with the technological, sensory, and stability requirements of a plant-based beverage. This process identified vitamin D, zinc, FOS, and L-leucine as the most suitable bioactive components, considering bioavailability, processing stability, and expected physiological effects. In the second phase, COSTA carried out the development and reformulation of the oat-based beverage to ensure nutritional adequacy, ingredient stability under thermal treatment, and organoleptic acceptability for older consumers. Finally, the third phase involves a clinical study, to be executed by Universitat Rovira i Virgili (URV), which aims to evaluate the effects of the newly developed fortified beverage on markers of immune function and systemic inflammation in community-dwelling older adults, with secondary outcomes including nutritional status and other health-related parameters relevant to ageing.

The multidisciplinary expertise of the consortium, including computational modelling, ingredient research, nutrition, food product development, and clinical epidemiology, ensures the feasibility of the project and the successful achievement of its objectives: AZTI provides evidence-based solutions for functional ingredients; COSTA develops innovative plant-based beverages; and URV contributes extensive experience in designing and implementing nutritional programs and clinical studies.

详细描述

Randomised, placebo-controlled, parallel, and double-blind intervention study.

There will be 4 visits in total, attended in the Centre MQ Reus:

  • Screening visit (V0, week -1):

  • Information to the volunteer and signature of the informed consent.

  • Revision of the eligibility criteria.

  • Elaboration of study clinical history.

  • Vital signs (blood pressure/resting heart rate).

  • Checking the concomitant medication.

  • Capillary blood sampling (Finger-prick blood sampling).

  • Anthropometry: waist circumference; hip; body weight and composition; height.

  • Delivery of the 3-day dietary record and the material for urine, saliva, and faeces recollection for V1.

  • Schedule the first visit and instructions (fasting).

- Basal visit (V1, week 0):

  • Isokinetic assessment (±5 days V1) *
  • Revision of the study clinical history.
  • Vital signs (blood pressure/resting heart rate).
  • Checking the concomitant medication.
  • Anthropometry: waist circumference; hip; body weight and composition; height.
  • Checking the physical activity (IPAQ-E).
  • Checking the quality of life (SF-36 Health survey questionnaire)
  • Checking the Fraility
  • Checking the Sleep quality
  • Checking the Depressive symptoms
  • Checking the Cognitive function (MMSE and Fototest)
  • Checking the Reported illness (adapted version of the FLU-PRO plus)
  • Ultrasound (muscle mass and abdominal fat).
  • Checking the Sarcopenic parameters (muscle strength based on grip dynamometry; skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 and appendicular skeletal muscle mass index (ASMI) based on bioimpedance analysis (BIA), low physical performance or physical function based on 4 m gait speed, m/s.
  • Checking the 3-day dietary record
  • Checking the Food Frequency Questionnaire (FFQ) adapted to the principal bioactive compounds (vitamin D, L-leucin, Zinc and FOS).
  • Checking the satiety scale (VAS)
  • Checking the Gastrointestinal health by Bristol Scale and Non-validated 5-item questionnaire
  • Blood sample extraction.
  • Collection of feaces samples.
  • Collection of urine samples.
  • Collection of salivary samples.
  • Balanced dietary guidelines for the elderly population explanation.
  • Schedule the next visit and instructions.
  • Administration of plant-based beverage (intervention or control product).
  • Assessment of product acceptance and purchase intention (After the first few home intakes (Week 1) by telephone) *In a subsample of n= 15 subjects, 5 days before or after the visit V10.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women ≥60 years old <80 years old.
  • Written informed consent provided before the initial screening visit.

排除标准

  • Hypoglycaemic treatment or type 1 and type 2 diabetes mellitus diagnosed.
  • Anaemia (haemoglobin ≤13 g/dL in men and ≤12 g/dL in women).
  • Intestinal malabsorption diseases, such as chron disease, colitis ulcerous, and irritable bowel syndrome.
  • Immune pathology or depressed immune system.
  • Use of antioxidants or nutritional supplements.
  • Known allergy or hypersensitivity to oat, coconut, or any formulation ingredient.
  • Renal diseases or history of hypercalcemia, sarcoidosis, or hyperparathyroidism.
  • History of inborn errors of metabolism affecting branched-chain amino acid metabolism.
  • Chronic alcoholism.
  • Current or past participation in a clinical trial or consumption of a research product in the 30 days before inclusion in the study.
  • Failure to follow the study guidelines.

研究组 & 干预措施

Functional plant-based beverage

Experimental

250 mL/day of the multi-ingredient plant-based functional beverage consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

干预措施: Functional plant-based beverage (Dietary Supplement)

Control beverage

Placebo Comparator

250mL/day of the plant-based beverage without functional selected study ingredients consumed at any time throughout the day + balanced dietary recommendations for the elderly population.

干预措施: Control Beverage (Dietary Supplement)

结局指标

主要结局

Change in serum hsCRP

时间窗: Visit 1 ("Week 0"), visit 3 ("Week 12")

The primary outcome measure will be the change in serum hsCRP (mg/dL) assessed by high-sensitivity immunoturbidimetry standardized methods on a Cobas Mira Plus autoanalyzer (Roche Diagnostics Systems, Madrid, Spain). It has been suggested that values \> 0.2 mg/dL of hsCRP increased the likelihood of developing cardiovascular disease or ischemic events. Consequently, changes in hsCRP involve changes in clinical impact.

次要结局

  • Inflammation markers and inflammatory cytokines(Visit 1 ("Week 0"), visit 3 ("Week 12"))
  • Oxidative markers(Visit 1 ("Week 0"), visit 3 ("Week 12"))
  • Immunologic parameters(Visit 1 ("week 0", visit 3 ("week 12"))
  • Immunologic parameters(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Glucose homeostasis(Visit 1 ("Week 0"), visit 3 ("Week 12"))
  • Glucose homeostasis(Visit 1 ("week 0", visit 3 ("week 12"))
  • Lipid profile(visit 1 ("week 0"), visit 3 ("week 12"))
  • Lipid profile(Visit 1 ("Week 0"), visit 3 ("Week 12"))
  • Anthropometric and muscle health measurements(Visit 0 ("week -1"), visit 1 ("week 0"), visit 3 ("week 12"))
  • Anthropometric and muscle health measurements(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Circulating micronutrients levels(Visit 1 ("week 1"), visit 3 ("week 12"))
  • Reported illness(Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12"))
  • Physical activity(Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12"))
  • Dietary record(Visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12"))
  • Life Quality(Visit 1 ("week 1"), visit 3 ("week 12"))
  • Frailty assessment(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Sleep Quality(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Depressive symptoms(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Cognitive Function(Visit 1 ("Week 0"), visit 3 ("week 12"))
  • Gut microbiota(Visit 1 ("week 0"), visit 3 ("week 12"))
  • Vital Signs(Visit 0 ("Week -1"), visit 1 ("week 0"), visit 2 ("week 6"), visit 3 ("week 12"))

研究者

发起方
University Rovira i Virgili
申办方类型
Other
责任方
Principal Investigator
主要研究者

Anna Pedret

Professor, Dr.

University Rovira i Virgili

研究点 (1)

Loading locations...

相似试验